CompoAtlas

Adrien Gagnon Féminex Post-méno

Natural health product licensed in Canada

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Pueraria omeiensis

Source : Racine

Extraction ratio : 15:1

Dry plant equivalent : 375 mg

Potency : 7.4 mg EAI

25 mgNot calculated
Glycine max

Source : Fève de soja

Potency : 2.75 mg ÉAI Genistein

Not specifiedNot calculated
Glycine max

Source : Fève de soja

Extraction ratio : 400:1

Dry plant equivalent : 10 g

Potency : 6.25 mg ÉAI Total isoflavones

25 mgNot calculated
Pueraria montana var. lobata

Source : Racine

40 mgNot calculated
Trifolium pratense

Source : Parties aériennes

Extraction ratio : 20:1

Dry plant equivalent : 2,500 mg

Potency : 0.0075 mg ÉAI Genistein

Not specifiedNot calculated
Trifolium pratense

Source : Parties aériennes

Extraction ratio : 15:1

Dry plant equivalent : 1,875 mg

Potency : 10 mg ÉAI Total isoflavones

125 mgNot calculated

Non-medicinal ingredients

Stéarate de magnésium, fructo-oligosaccharide, Dioxyde de silicium colloïdal, Maltodextrine, Gélatine, Eau purifiée

PopulationAgeQuantity per servingFrequency
Femmes en postménopauseNot specified4 CapsuleNot specified

Uses authorised in Canada

Combiné à un apport suffisant en calcium et en vitamine D, aide à réduire la perte de la densité minérale osseuse (DMO) chez les femmes en post-ménopause.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Product record

Other names
A.G. Sélect Isolfavones
Licence holder
Santé Naturelle (A.G.) Ltée
NPN or DIN-HM
80016676
Status
Active licence
Licence date
12 March 2010
Revision date
6 August 2015
Form
Capsule
Route of administration
Orale
Application type
Non traditionnelle

Source

Official Health Canada record, licence 80016676

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Glycine max
    Read the warning, when it applies and the studies cited

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

Photograph the packaging

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Adrien Gagnon Féminex Post-méno”, https://compoatlas.com/en/supplements/canada/80016676-adrien-gagnon-feminex-post-meno, updated 6 August 2015.

List recorded in 2015. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line